ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 302

Resource Utilization in a US Sample of Patients with Sporadic Inclusion Body Myositis

Victoria Barghout1, Carla DeMuro2, Bob Goldberg3, Mark A Price2, Linda Lowes4, Gorana capkun-Niggli5, Valerie Williams6 and Brian Tseng7, 1VEB HealthCare LLC, Morristown, NJ, 2RTI Health Solutions, North Carolina, NC, 3The Myositis Association, Alexandria, VA, 4Nationwide Children’s Hospital, Columbus, OH, 5Novartis Pharmaceuticals Corporation, Basel, Switzerland, 6Psychometrics, RTI Health Solutions, North Carolina, NC, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Muscle Biology, Myositis and Myopathies Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Sporadic Inclusion Body Myositis (sIBM) is a progressive, idiopathic inflammatory myopathy characterized by dysphagia, weakness of proximal and distal muscles and atrophy. This cross-sectional study aims to characterize the socioeconomic burden of sIBM patients in the United States (US).

Methods: sIBM patients registered for The Myositis Association 2013 and 2014 annual patient conferences completed the Skeletal Muscle Activity and Resource Tool for sIBM (SMART-sIBM). The SMART-sIBM is a measure of self-reported resource utilization developed with extensive sIBM patient input and cognitively tested (sIBM patient interviews) to ensure its relevance to the sIBM patient population. The SMART-sIBM is designed to characterize direct and out-of-pocket expenses including items not reimbursed by US third-party payers. Patients completed the SMART-sIBM either electronically or using paper forms.

Results: Of 102 unique sIBM patients who participated, 31 were assessed both years. For the overall sample, mean age was 67.2 years (range 49–88), and the majority were male (62%), Caucasian (96%). Mean (±SD) number of years since diagnosis was 5.3 (±4.3) and years since first symptoms was 11.3 (±6.4). Approximately 36% of participants were ambulatory without use of an assistive device, 36% used an aid/brace, 17% used power mobility for long distances, 7% used power mobility most of the time, and 4% were not able to walk or stand. The average number of falls in the past month was <1 (range: 0–4) and the average number of healthcare visits due to falls in the past 12 months was 0.71 (±1.8, range: 0–12). In the past 6 months 62% of participants reported visiting specialists for their sIBM and 39% visited a general practitioner. A large majority of sIBM patients (68.4%) reported that they had to make non-reimbursed modifications to their house, apartment, or car because of their sIBM, and 76.5% reported non-reimbursed purchases of special equipment, devices, or aids since diagnosis with sIBM. Paid help for household tasks was required by 37% of participants, 60% relied on unpaid caregivers (87.5% spouse), and 42% reported a change in job status due to sIBM-related functional limitations.

Conclusion:

This study provides resource utilization data for the first time in a US sample of patients with sIBM. sIBM patients experience considerable financial burden, including important out-of-pocket expenses, due to their physical disability and loss of independence.


Disclosure: V. Barghout, Novartis Pharmaceutical Corporation, 5; C. DeMuro, Novartis Pharmaceutical Corporation, RTI Health Soultions, 9; B. Goldberg, None; M. A. Price, Novartis Pharmaceutical Corporation, RTI Health Solutions, 9; L. Lowes, Novartis Pharmaceutical Corporation, 5; G. capkun-Niggli, Novartis Pharmaceutical Corporation, 3; V. Williams, Novartis Pharmaceutical Corporation, RTI Health Solutions, 9; B. Tseng, Novartis Pharmaceutical Corporation, 3.

To cite this abstract in AMA style:

Barghout V, DeMuro C, Goldberg B, Price MA, Lowes L, capkun-Niggli G, Williams V, Tseng B. Resource Utilization in a US Sample of Patients with Sporadic Inclusion Body Myositis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/resource-utilization-in-a-us-sample-of-patients-with-sporadic-inclusion-body-myositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/resource-utilization-in-a-us-sample-of-patients-with-sporadic-inclusion-body-myositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology